Publication date: September 8, 2023
KIELTYKA GLADKOWSKI was present at the EMERGING TECHNOLOGIES FOR DEFENSE (see link to speakers) conference in Washington, organized by The National Defense Industrial Association in cooperation with Emerging Technologies Institute.
Publication date: August 16, 2023
Malgorzata Kieltyka has been appointed as the Co-Chair of the Life Science Committee of the American Bar Association International Law Section for the year 2023 – 2024.
K. Jakub Gladkowski has been appointed as the Vice-Chair of the Life Science Committee of the American Bar Association International Law Section for the year 2023 – 2024.
Publication date: June 13, 2023
In recent years, the growing interest in the medical use of cannabis has opened up new opportunities in the pharmaceutical industry. In Poland, where the sale of cannabis only for the medical purposes is strictly regulated, the introduction of medical cannabis to the market is associated with legal and administrative challenges, and at the same time opens up prospects for new solutions for patients with various diseases. This case study analyses the process of introducing the sale of medical cannabis in Poland and its impact on the online pharmaceutical industry. It also points to the legal problems of the medical cannabis sales system from the perspective of the common phenomenon of the need for Polish patients to order medicine online and teleconsultations.
Before 2017, cannabis was illegal in Poland for both medical and non-medical use. However, in 2017, the Polish parliament passed a law that allows the use of medical cannabis under the supervision of a doctor for patients suffering from certain diseases.
Publication date: June 06, 2023
Pursuant to Art. 7 (2) of the Act on package travel and linked travel arrangements, there is an obligation to conclude an insurance contract in a specific amount. This provision provides that statutory obligations are fulfilled by tour operators and entrepreneurs facilitating linked travel arrangements by:
1) conclusion of a bank guarantee or an insurance guarantee in accordance with the template form and the provisions specifying the minimum amount of the guarantee sum or
2) conclusion of an insurance contract for travelers inaccordance with the form template and the provisions specifying the minimum amount of the sum insured, or
3) concluding a contract for a travel escrow account in accordance with the model of this contract and accepting travellers’ payments only to this account, if they provide package travel or facilitate the purchase of linked travel arrangements provided only on the territory of the Republic of Poland;
4) making timely payments of contributions in the due amount to the Tourist Guarantee Fund.
Publication date: June 06, 2023
Biosimilar medicines, also known as biosimilars, are used in medicine to treat severe and chronic conditions such as cancer, diabetes and autoimmune diseases. Biosimilars – true to their name, they are similar to existing biological reference drugs. They are produced using living organisms or their cells, such as proteins, antibodies and other biological substances. These pharmaceuticals are also produced using biological processes but are not identical to the original reference medicines.
Biosimilars must meet certain criteria to be approved by the relevant regulatory authorities. They must be similar in quality, efficacy and safety to reference medicines. This means that they must have similar biological properties, such as action, mode of action and side effects, to those of the reference drugs.
